Bibliography
- Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
- Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265.
- Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly invitro by taxol. Nature. 1979;277(5698):665–667.
- Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325–2327.
- Cragg GM, Kingston DGI, Newman DJ. Anticancer agents from natural products. Boca Raton (FL): CRC Press; 2012.
- Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drug. 1995;6(3):339-55, 363-8.
- Gueritte F. General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr Pharm Design. 2001;7(13):1229–1249.
- FDA. FDA approves new treatment for advanced head and neck cancer [ Press Release]. [Internet]. 2006 [cited 2006 Oct 18]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108771.htm
- Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer. 1996;32A(6):1039–1050.
- Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11:298–305.
- Darshan MS LM, Thadani-Mulero M, Levy BP, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71:6019–6029.
- Giannakakou P, Plymate SR. Identifying taxane sensitivity in prostate cancer patients. WO2014047285A1. 2014.
- de Leeuw RB-BL, Schiewer MJ, Ciment SJ, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21:795–807.
- Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221(4617):1285–1288.
- FDA. FDA labeling information-Javtana (cabazitaxel) [Internet]; 2010 [cited 2010 Jun]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf
- Abidi A. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother. 2013;4(4):230–237.
• This review article summarizes the characteristics of cabazitaxel, its applications to hormone-resistant prostate cancer treatment and future prospects.
- Bissery MC, Bouchard H, Riou J, et al. Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res. 2000;41:214.
- Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723–730.
- De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
- Galsky MD, Dritselis A, Kirkpatrick P, et al. Cabazitaxel. Nat Rev Drug Discov. 2010;9(9):677–678.
- Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res. 2012;18(24):6574–6579.
- Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547–1552.
- Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334(2):157–175.
- He Z, Schulz A, Wan X, et al. Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release. 2015;20:867–875.
- Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317–1324.
• This article describes salient features of ABI-007 (Abraxane) in the preclinical to clinical drug development in comparison to the standard formulation of paclitaxel.
- Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8(5):1038–1044.
- Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel cremphor-EL-free formulation of paclitaxel. Nanomedicine. 2007;2(4):415–423.
- Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther. 2012;6:371–384.
- Benettaib B, Elias I, Renschler M, et al. Methods using pharmaceutical compositions comprising nanoparticles that comprise a taxane and an albumin for treatment of pediatric solid tumor. WO2014143613A1. 2014.
- Desai NP, Soon-Shiong P. Use of nanoparticles comprising taxanes and albumin in combination with chemotherapeutic agents for treatment of pancreatic cancer. WO2011153010A1. 2011.
- Yeo W, Wong N. Nanoparticles formulation comprising taxane and an albumin for treatment of hepatocellular carcinoma. WO2011119988A1. 2011.
- Desai NP, Renschler M. Methods of treating melanoma comprising nanoparticles comprising taxane and a carrier protein. WO2014123612A1. 2014.
- Desai NP, Trieu V. Combination therapy with thiocolchicine derivatives for treatment of proliferative disease such as cancer. WO2010105172A1. 2010.
- Desai NP, Soon-Shiong P. Nanoparticle formulations comprising a taxane and an albumin in combination with other chemotherapeutic agents for the treatment of proliferative diseases such as cancer. WO2011156119A1. 2011.
- FDA [Internet]. 2013. [cited 2013 Sep 6]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367442.htm
- Sanofi [Internet]. 2010 [cited 2010 Aug 5]. Available from: http://www.news.sanofi.us/index.php?s=33507&item=118530
- Parente Duena A, Garces GJ, Mis Vizcaino R. Injectable taxane pharmaceutical composition. WO2010015400A2. 2010.
- Tsai CJ, Jang SH, Huang T-M, et al. Stable pharmaceutical formulation of cabazitaxel. US20140171495 A1. 2014.
- Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13:813–827.
- Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother. 2009;63:603–607.
- AAStocks [Internet]. 2015 [cited 2015 May 29]. http://www.aastocks.com/en/stocks/analysis/company-fundamental/?symbol=02186
- Koudelka S, Turanek J. Liposomal paclitaxel formulations. J Control Release. 2012;163(3):322–334.
- Crawford TC, Fetzer OS, Reiter LA, et al. Preparation of cyclodextrin-based polymers for therapeutic delivery as antitumor agents. US20120058971A1. 2012.
- Desu HR, Patel KR, Pejaver SK, et al. Methods and compositions for delivery of taxanes in stable oil-in-water emulsions. US20110166214A1. 2011.
- Vavia PR, Patel KDK. Amino acid surfactant based nanocarrier for drug targeting. IN2010MU02958A. 2014.
- Li S-D, Ernsting MJ Cellulose-based nanoparticles for drug delivery for cancer treatment. WO2014015422A1. 2014.
- Nabeta K. Non-aqueous taxane nanodispersion formulations and methods of using the same for treatment of proliferative diseases. US20140094509A1. 2014.
- Zale SE, Troiano G, Ali MM, et al. Drug loaded polymeric nanoparticles and methods of making and using same. WO2010005721A2. 2010.
- Seeney CE, Klostergaard J, Yuill WA, et al. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using. US20110130616A1. 2011.
- Hoye TR, Wohl A, Macosko CW, et al. Silicate prodrugs and nanoparticles. WO2012166949A1. 2012.
- Yin R, Pan J, Zhang Y, et al. Modified branched homopolymers forming aggregates with taxanes for nanoparticles. WO2014123791A1. 2014.
- Karmali RA. Pharmaceutical compositions containing paclitaxel orotate. WO2012148494A2. 2012.
- Beijnen JH, Schellens JHM, Moes J, et al. Solid pharmaceutical compositions comprising a taxane. WO2010020799A2. 2010.
- Modi P. Oral formulations of chemotherapeutic agents. CA2843943A1. 2014.
- Robert F, Harper K, Ackerman J, et al. A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naive patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65(2):227–234.
- Metzger-Filho O, Moulin C, De Azambuja E, et al. Larotaxel: broadening the road with new taxanes. Expert Opin Investig Drugs. 2009;18(8):1183–1189.
- Dieras V, Viens P, Veyret C, et al. Larotaxel (L) in combination with trastuzumab in patients with HER2+ metastasis breast cancer (MBC): interim analysis of an open phase II label study. J Clin Oncol. 2008;26:1070.
- Ojima I, Kamath A, Seitz JD. Taxol, taxoids and related taxanes. In: Hanessian S, editor. Natural products in medicinal chemistry. Weinheim (Germany): Wiley-VCH; 2013. p. 127–180.
•• This book chapter summarizes the clinical and preclinical developments of new-generation taxoids and taxanes upto 2011 and complements the present EOTP review.
- Sternberg CN, Skoneczna IA, Castellano D, et al. Larotaxel with cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology. 2013;85(4):208–215.
- Beer M, Lenaz L, Amadori D. Phase II study of ortataxel in taxane-resistant breast cancer. J Clin Oncol. 2008;26:1066.
- ClinicalTrials.gov. An Efficacy Study Of Ortataxel In Recurrent Glioblastoma [Internet]. 2013 [cited 2013 Oct 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01989884
- Moore M, Jones C, Harker G, et al. Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. J Clin Oncol. 2006;24:3591.
- Roche M, Kyriakou H, Seiden M. Drug evaluation: tesetaxel–an oral semisynthetic taxane derivative. Curr Opin Investig Drugs. 2006;7(12):1092–1099.
- Beeram M, Papadopoulos K, Pantnaik A, et al. Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent. J Clin Oncol. 2010;28:13075.
- Ramanathan RK, Picus J, Raftopoulos H, et al. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008;61(3):453–458.
- Camps C, Felip E, Sanchez JM, et al., on behalf of Spanish Lung Cancer Group. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol. 2005;16:4597–601.
- Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res. 2001;7(10):3229–3238.
- Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22(4):787–793.
- Bradley MO, Swindell CS, Anthony FH, et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release. 2001;74(1–3):233–236.
- Paz-Ares L, Ross H, O’Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008;98(10):1608–1613.
- Jeyapalan SA, G. M, D. J. A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas. J Clin Oncol. 2011;29(suppl):2036.
- Dipetrillo T, Suntharalingam M, Ng T, et al. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol. 2012;35(1):64–67.
- Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf. 2003;2(2):141–146.
- Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer. 2004;11(1):82–85.
- FDA [Internet]. 2012 [cited 2012 Jun 8]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm307549.htm
- MPR [Internet]. 2013 [cited 2013 Sep 12]. Available from: http://www.empr.com/drugs-in-the-pipeline/fda-fast-tracks-ganetespib-for-non-small-cell-lung-adenocarcinoma/article/311445/
- Ramalingam SS, Goss GD, Andric ZG, et al. A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). J Clin Oncol. 2013;31(18):CRA8007.
- NIH [Internet]. 2013 [cited 2013 Feb 4]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01798485
- Hei Y-J, Yao B. Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset of Asian patients. WO2012142325A1. 2012.
- Conlin AK, Seidman AD, Bach A, et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010;10(4):281–287.
- Desai NP, Tao C, De T, et al. Nanoparticle formulations comprising taxane derivatives for cancer treatment. WO2010118365A1. 2010.
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
• This article describes unanticipated high efficacy of nab-paclitaxel (Abraxane) in pancreatic cancer in combitation with gemcitabine.
- Desai NP, Soon-Shiong P. Nanoparticle formulations comprising a taxane and an albumin in combination with other chemotherapeutic agents for treatment of cancer. WO2011123393A1. 2011.
- Vukovic V. Specific cancer treatment regimens with ganetespib. WO2014189937A1. 2014.
- NIH [Internet]. 2015 [cited 2015 Jun 15]. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT01962948?term=paclitaxel+and+ganetespib&rank=1
- Mahammedi H, Planchat H, Cure H, et al. Pilot phase II study with docetaxel in combination with curcuminoids in patients with hormone-resistant prostate cancer (HRPC). J Clin Oncol. 2011;29. suppl;abstr e15069.
- Barthomeuf C, Chollet P, Cure H, et al. Methods and pharmaceutical compositions for the treatment of hormone-refractory prostate cancers. WO2012146706A1. 2012.
- Duksin C, Tessler S. Methods for treating non-small cell lung cancer using combination of taxanes, an anti-clusterin oligonucleotide and platinum-based chemotherapeutic agents. WO2012156817A2. 2012.
- Kubota K, Ichinose Y, Scagliotti G, et al. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Ann Oncol. 2014;25(2):529–536.
- Bahleda R, Sessa C, Del Conte G, et al. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2014;32(6):1188–1196.
- Cohen P, Oprea IC. An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative WO2011158206A1. 2011.
- Gupta S. Novel antitumoral use of cabazitaxel in metastatic prostate cancer. WO2011051894A1. 2011.
- Patel PH, Peterson AC. Anti-c-Met antibodies and taxanes combined with anti-VEGR antibodies for treatment of ER-/PR-/HER- metastatic breast cancer. US20110287003A1. 2011.
- Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30(4):362–371.
- Weinreich DM. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane WO2011038139A1. 2011.
- Desai NP, Soon-Shiong P. Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer. US20100112077A1. 2010.
- Somer BG, Schwartzberg LS, Arena FP, et al. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J Clin Oncol. 2007;25:18.
- Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–471.
- McCormack PL. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. Drugs. 2013;73(13):1491–1502.
- Baselga J, Manikhas A, Cortes J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2014;25(3):592–598.
- Rozencweig M, Goldfarb RH, Forenza S. Non-pegylated liposomal doxorubicin triple combination therapy. US8026267B2. 2011.
- Robert N, Krekow L, Stokoe C, et al. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Res Treat. 2011;125(1):115–120.
- Desai NP, Soon-Shiong P. Use of nanoparticles comprising taxanes and albumin in combination with chemotherapeutic agents for the treatment of bladder cancer. WO2011153009A1. 2011.
- Smith DC, Grivas P, Daignault S, et al. A phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder. J Clin Oncol. 2011;29. suppl 7;abstr 244.
- Chirgwin J, Chua SL. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review. Breast J. 2011;20:5.
- Lianos GD, Vlachos K, Zoras O, et al. Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther. 2014;7:491–500.
- Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligandtargeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14:203–219.
- Castaigne J-P, Demeule M, Lawrence B. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog. WO2010121379A1. 2010.
- Demeule M, Regina A, Che C, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324(3):1064–1072.
- Bertrand Y, Currie JC, Demeule M, et al. Transport characteristics of a novel peptide platform for CNS therapeutics. J Cell Mol Med. 2010;14(12):2827–2839.
- Bowen BC, Bradley WG. Amyotrophic lateral sclerosis: the search for a spectroscopic marker of upper motoneuron involvement. Arch Neurol. 2001;58(5):714–716.
- Ojima I, Chen J, Sun L, et al. Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem. 2008;51(11):3203–3221.
- Ojima I, Das M. Recent advances in the chemistry and biology of new generation taxoids. J Nat Prod. 2009;72(3):554–565.
- Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nature Rev Drug Discov. 2007;6:115–120.
- Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267–284.
- Botchkina GI, Zuniga ES, Das M, et al. New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheriods induced by purified colon tumor-initiating cells. Mol Cancer. 2010;9:192–204.
• This article revealed the activity of a second-generation taxoid against colon cancer stem cells for the first time.
- Zuniga ES. Design, synthesis and biological evaluation of new-generation taxoid-based tumor-targeting drug conjugates [ Ph.D. thesis]. Stony Brook University; 2012.
- Kuznetsova L, Sun L, Chen J, et al. Synthesis and biological evaluation of novel 3ʹ-difluorovinyl taxoids. J Fluorine Chem. 2012;143:177–188.
- Otova B, Ojima I, Vaclavikova R, et al. Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes. Invest New Drugs. 2012;30(3):991–1002.
- Ojima I. Taxoid-Fatty Acid Conjugates and Pharmaceutical Compositions Thereof. US7820839B2. 2010.
- Seitz J, Ojima I. Drug conjugates with polyunsaturated fatty acids. In: Kratz F, Senter P, Steinhagen H, editors. Drug delivery in oncology – from research concepts to cancer therapy. Vol. 3. Weinheim (Germany): Wiley-VCH; 2011. p. 1323–1360.
- Jing Y-R, Zhou W, Li W-L, et al. The synthesis of novel taxoids for oral administration. Bioorg Med Chem. 2014;22:194–203.
- McChesney JD, Venkataraman S, Henri JT. Preparation of taxane analogues for the treatment of cancer and neurodegenerative disorders. WO2011028571A1. 2011.
- McChesney JD, Henri JT, Venkataraman SK, et al. Taxane and abeo-taxane analogs as antitumor agents. WO2013106029A1. 2013.
- Kozlowski A, Riley TA, McManus SP. Preparation of deuterated and/or fluorinated taxane derivatives. WO2012088433A1. 2012.
- Chari RVJ. Potent cell-binding agent drug conjugates. WO2009134870A1. 2009.
- Chari RVJ. Potent cell-binding agent drug conjugates. US20100092495A1. 2010.
- Liu J, King D. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal cysteine-containing extensions. WO2009026274A1. 2009.
- Hamada H, Mikuni K, Nakanishi K, et al. Antitumor compositions containing taxoid derivatives covalently linked to tumor-specific antibody. US20070025995A1. 2007.
- Gastaldi D, Zonari D, Dosio F. Targeted taxane delivery systems: recent advances. Drug Deliv Lett. 2011;1(2):105–117.
- Klostergaard J, Farquhar D, Ghosh SC, et al. Anticancer agent-hyaluronic acid conjugate compositions and methods of use. WO2008134528A1. 2008.
- Maneval DC, Shepard HM, Thompson CB. Protein sequences of human hyaluronidase and combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane. WO2013151774A1. 2013.
- Fazioni S, Hovda K, Livi V, et al. Method for determining the amount of conjugated taxane in poly(glutamic acid)-taxane conjugates. WO2008107174A1. 2008.
- Bai H, Tsang KY, Jin Y, et al. Large scale process for preparing poly(glutamyl-glutamate) conjugates for anticancer drug delivery. WO2014175898A1. 2014.
- Kozlowski A, Riley TA, McManus SP. Multi-arm polymeric prodrug conjugates of taxane-based compounds as a drug delivery systems. WO2012088422A1. 2012.
- Scripture CD, Figg WD, Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol. 2006;4(2):165–172.
- Mutz MW, Webb R III, Gestwicki JE. Therapeutic agents having reduced toxicity. WO2011130317A2. 2011.
- Sengupta S, Kulkarni A, Rao P, et al. Compositions of a chemotherapeutic agent-cholesterol conjugate for treating cancer and methods for making the same. WO2013188763A1. 2013.
- Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56:1127–1141.
- Vlahov IR, Leamon CP. Engineering folate−drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem. 2012;23:1357−1369.
- Russell-Jones G, McTavish K, McEwan J, et al. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem. 2004;98:1625–1633.
- Chen SY, Zhao XR, Chen JY, et al. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjugate Chem. 2010;21(5):979–987.
- Ojima I, Zuniga ES, Berger WT, et al. Tumor-targeting drug delivery of new generation taxoids. Future Med Chem. 2012;4:33–50.
• This review article summarizes various approaches to the tumor-targeted drug delivery of new-generation taxoids.
- Ojima I. Drug Conjugate. US 7,282,590 B2. 2007.
- Ojima I. Drug Conjugates with heterobifunctional linkers. US 7,847,119 B2. 2010.
- Chen J, Chen S, Zhao X, et al. Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc. 2008;130:16778–16785.
- Vineberg JG. Design, synthesis, and biological evaluation of novel taxoid-based drug conjugates and theranostic imaging agents towards tumor-targeted chemotherapy [ Ph.D. thesis]. Stony Brook University; 2014.
- Rayan A. Conjugate of a taxane and biotin and uses thereof. WO2014191989A1. 2014.
- Gebhard JR, Vollmer D, Patel D, et al. Cobalamin taxane bioconjugates useful as oral anti-cancer or anti-angiogenic drugs. WO2008115805A2. 2008.
- Gebhard JR, Patel D. Cobalamin taxane bioconjugates for treating eye disease. WO2010088287A1. 2010.
- Gebhard JR, Patel D. Taxane compounds for treating eye disease. US20100016256A1. 2010.
- Seitz JD, Vineberg JG, Herlihy E, et al. Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate. Bioorg Med Chem. 2015;23(9):2187–2194.
- Armstrong RC, Wierenga WD. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment WO2010105016A1. 2010.
- Hart CP, Sun JD, Elenbaas BA, et al. Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane. WO2015013448A1. 2015.
- Chakravarty A, Ecsedy JA, Kleinfield RW, et al. Methods of treating cancer using aurora kinase inhibitors. WO2013142491A1. 2013.
- Hancox UJ, Cosulich S, Davies BR. Combination treatment of cancer comprising 8-[(1R)-1-(3,5-difluorophenylamino)ethyl]-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide and a taxane. WO2014135851 A1. 2014.
- Liu L, Gerson S. O6-methylguanine methyltransferase (MGMT) inhibitor in combination with other chemotherapeutic agents for the treatment of neoplastic disorders. US8791081B2. 2014.
- Wengner AM, Siemeister G. Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer. WO2014198776A1. 2014.
- Robertson FM. Combination therapy comprising paclitaxel and romidepsin for treating an inflammatory breast cancer. WO2013085902A1. 2013.
- Davies BR. Pharmaceutical combination comprising AZD5363 and taxanes for treatment of cancer. WO2012131399A1. 2012.
- Ulivi P, Arienti C, Zoli W, et al. In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Curr Cancer Drug Targets. 2010;10:600–610.
- Fodstad O. B7-H3 antagonists and taxanes for treating cancer. WO2012004410A1. 2012.
- Blackman RK, Foley KP, Proia D. Combination therapy using with taxanes and triazolone HSP90 inhibitory compounds for treatment of cancer. WO2011049946A1. 2011.
- Patel L, Williams S, Wilding I, et al. Combination therapy comprising a taxane and a sigma receptor ligand such as rimcazole. WO2010128309A1. 2010.
- Shankar G, Bentzien F, Lamb P, et al. Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents for the treatment of cancer. WO2010045601A2. 2010.